Evidence map›Paper›PMID 35207714›Full record

ArticleJournal of personalized medicine2022

Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group.

Chung-Yu Lin, Han-Yu Weng, Ta-Yao Tai, Hsi-Chin Wu, Wen-Chi Chen, Chung-Hsin Chen, Chao-Yuan Huang, Chi-Wen Lo, Chih-Chin Yu, Chung-You Tsai and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 16 institutions in 1 country.

Chung-Yu LinDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
Han-Yu WengDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Ta-Yao TaiDepartment of Urology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.
Hsi-Chin WuDepartment of Urology, China Medical University Hospital, Taichung 404, Taiwan.
Wen-Chi ChenDepartment of Urology, China Medical University Hospital, Taichung 404, Taiwan.
Chung-Hsin ChenDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan.ORCID 0000-0002-4921-5315
Chao-Yuan HuangDepartment of Urology, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Chi-Wen LoDivision of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City 231, Taiwan.
Chih-Chin YuDivision of Urology, Department of Surgery, Taipei Tzu Chi Hospital, The Buddhist Medical Foundation, New Taipei City 231, Taiwan.ORCID 0000-0002-1344-1505
Chung-You TsaiDivision of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
Wei-Che WuDivision of Urology, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
Yuan-Hong JiangDepartment of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien 970, Taiwan.
Yu-Khun LeeDepartment of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien 970, Taiwan.ORCID 0000-0002-9325-9868
Thomas Y HsuehDivision of Urology, Department of Surgery, Taipei City Hospital Renai Branch, Taipei 106, Taiwan.
Allen W ChiuCollege of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Bing-Juin ChiangCollege of Medicine, Fu-Jen Catholic University, New Taipei City 242, Taiwan.
Hsu-Che HuangDivision of Urology, Department of Surgery, Cardinal Tien Hospital, New Taipei City 231, Taiwan.
I-Hsuan Alan ChenDivision of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan.
Yung-Tai ChenDepartment of Urology, Taiwan Adventist Hospital, Taipei 105, Taiwan.
Wei-Yu LinDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Chia-Yi 613, Taiwan.ORCID 0000-0002-6090-1084
Chia-Chang WuDepartment of Urology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 235, Taiwan.
Yao-Chou TsaiDepartment of Urology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-2833-5609
Hsiang-Ying LeeDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.ORCID 0000-0003-2405-4874
Wei-Ming LiDepartment of Urology, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.
Kaohsiung Medical University · TWTzu Chi University · TWChina Medical University · TWNational Cheng Kung University Hospital · TWNational Taiwan University Hospital · TWNational Yang Ming Chiao Tung University · TWChang Gung University of Science and Technology · TWFu Jen Catholic University · TWKaohsiung Veterans General Hospital · TWMing Chuan University · TWNational Taiwan Normal University · TWNational Taiwan University · TWTaipei Medical University Hospital · TWTaipei Medical University-Shuang Ho Hospital · TWTaipei Tzu Chi Hospital · TWTaiwan Adventist Hospital · TW

Funding

Kaohsiung Medical University Hospital, Taiwan KMUH108-8M53, KMUH109- 9R60, KMUH-DK(C)-110006Kaohsiung Medical University Research Center, Taiwan KMU-TC109B05Ministry of Science and Technology, Taiwan MOST109-2314-B-037-110-MY3, MOST110-2321-B-037-002
6 · The paper itself

Abstract

The clinical efficacy of adjuvant chemotherapy in upper tract urothelial carcinoma (UTUC) is unclear. We aimed to assess the therapeutic outcomes of adjuvant chemotherapy in patients with advanced UTUC (pT3-T4) after radical nephroureterectomy (RNU). We retrospectively reviewed the data of 2108 patients from the Taiwan UTUC Collaboration Group between 1988 and 2018. Comprehensive clinical features, pathological characteristics, and survival outcomes were recorded. Univariate and multivariate Cox proportional hazards models were used to evaluate overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS). Of the 533 patients with advanced UTUC included, 161 (30.2%) received adjuvant chemotherapy. In the multivariate analysis, adjuvant chemotherapy was significantly associated with a reduced risk of overall death (hazard ratio (HR), 0.599; 95% confidence interval (CI), 0.419-0.857;

Indexed as

chemotherapyprognosisupper tract urothelial carcinoma

Identifiers

PMID35207714
PMCPMC8877034
OpenAlexW4210336419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.